Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment

Abousalman‐Rezvani, Zahra; Refaat, Ahmed; Dehghankelishadi, Pouya; Roghani‐Mamaqani, Hossein; Esser, Lars; Voelcker, Nicolas H.

doi:10.1002/adhm.202302902

Cited by 1 publication

(1 citation statement)

References 316 publications

(362 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-based nanoparticles represent a promising avenue for anticancer drug delivery, serving as sophisticated and comprehensive nano-scale delivery systems for diverse bioactive substances. 24 , 25 These lipid nanocarriers use various functional groups on their surfaces to facilitate the attachment of molecules such as antibodies, polysaccharides, and medications, thereby enhancing drug delivery to cancer cells. Their advantages include rapid absorption, minimal adverse effects, ease of production, and excellent in vivo stability.…”

Section: Introductionmentioning

confidence: 99%

Construction and Evaluation of BAL-PTX Co-Loaded Lipid Nanosystem for Promoting the Anti-Lung Cancer Efficacy of Paclitaxel and Reducing the Toxicity of Chemotherapeutic Drugs

Chen,

Wei,

Yin

et al. 2024

IJN

View full text Add to dashboard Cite

Purpose The present study aimed to develop a lipid nanoplatform, denoted as “BAL-PTX-LN”, co-loaded with chiral baicalin derivatives (BAL) and paclitaxel (PTX) to promote the anti-lung cancer efficacy of paclitaxel and reduce the toxicity of chemotherapeutic drugs. Methods BAL-PTX-LN was optimized through central composite design based on a single-factor experiments. BAL-PTX-LN was evaluated by TEM, particle size, encapsulation efficiency, hemolysis rate, release kinetics and stability. And was evaluated by pharmacokinetics and the antitumor efficacy studied both in vitro and in vivo. The in vivo safety profile of the formulation was assessed using hematoxylin and eosin (HE) staining. Results BAL-PTX-LN exhibited spherical morphology with a particle size of 134.36 ± 3.18 nm, PDI of 0.24 ± 0.02, and with an encapsulation efficiency exceeding 90%, BAL-PTX-LN remained stable after 180 days storage. In vitro release studies revealed a zero-order kinetic model of PTX from the liposomal formulation. No hemolysis was observed in the preparation group. Pharmacokinetic analysis of PTX in the BAL-PTX-LN group revealed an approximately three-fold higher bioavailability and twice longer t 1/2 compared to the bulk drug group. Furthermore, the IC 50 of BAL-PTX-LN decreased by 2.35 times (13.48 μg/mL vs 31.722 μg/mL) and the apoptosis rate increased by 1.82 times (29.38% vs 16.13%) at 24 h compared to the PTX group. In tumor-bearing nude mice, the BAL-PTX-LN formulation exhibited a two-fold higher tumor inhibition rate compared to the PTX group (62.83% vs 29.95%), accompanied by a ten-fold decrease in Ki67 expression (4.26% vs 45.88%). Interestingly, HE staining revealed no pathological changes in tissues from the BAL-PTX-LN group, whereas tissues from the PTX group exhibited pathological changes and tumor cell infiltration. Conclusion BAL-PTX-LN improves the therapeutic effect of poorly soluble chemotherapeutic drugs on lung cancer, which is anticipated to emerge as a viable therapeutic agent for lung cancer in clinical applications.

show abstract

Section: Introductionmentioning

confidence: 99%